PLAC8L1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: PLAC8L1

NCBI ID: G153770

PLAC8L1

Other Name(s): PLAC8-like protein 1 | PL8L1_HUMAN | PLAC8 like 1

PLAC8L1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

PLAC8L1, also known as PLAC8-like protein 1, is a protein that is expressed in various tissues throughout the body. It is a member of the PLAC8 family of proteins, which are known for their role in cell-cell adhesion. PLAC8L1 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, PLAC8L1 has become a focus of interest for researchers and drug developers.

One of the key functions of PLAC8L1 is its role in cell-cell adhesion. This protein helps to regulate the interactions between cells, allowing them to stick together and form tissues. PLAC8L1 is also involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and function.

In addition to its role in cell-cell adhesion, PLAC8L1 has also been shown to play a role in the development and progression of various diseases. For example, studies have shown that PLAC8L1 is overexpressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that PLAC8L1 may be a useful biomarker or drug target in these diseases.

One of the potential benefits of targeting PLAC8L1 is its potential to disrupt the formation of cancer cells. Cancer cells often rely on the ability to stick together and form tissues to grow and survive. By inhibiting the interactions between cells, PLAC8L1 has been shown to be effective in inhibiting the growth and spread of cancer cells. This makes PLAC8L1 an attractive potential drug target for cancer therapy.

Another potential benefit of targeting PLAC8L1 is its potential to treat neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells. PLAC8L1 has been shown to be involved in the development and progression of these diseases, and may be a useful target for therapeutic intervention.

PLAC8L1 has also been shown to be involved in the development and progression of autoimmune disorders. Autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, are characterized by the immune system attacking the body's own tissues. PLAC8L1 has been shown to be involved in the development and progression of these disorders, and may be a useful target for therapeutic intervention.

In conclusion, PLAC8L1 is a protein that has been shown to play a role in the development and progression of various diseases. As a result, PLAC8L1 has become a focus of interest for researchers and drug developers. Studies have shown that PLAC8L1 can be effective in inhibiting the growth and spread of cancer cells, and may be a useful drug target for cancer therapy. Additionally, PLAC8L1 may also be a useful target for treating neurodegenerative diseases and autoimmune disorders. Further research is needed to fully understand the role of PLAC8L1 in these diseases and to develop effective treatments.

Protein Name: PLAC8 Like 1

The "PLAC8L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLAC8L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets